CANMAB 440MG

Canmab 440mg Injection contains Trastuzumab as its active ingredient, which is indicated for use in HER2 breast cancer. In patients who are HER2 positive, the breast cancer cells predominantly consist of HER2 proteins that promote the rapid growth of cancer tumors by acting as signals to the cancerous cells. This medication is also utilized for treating metastatic gastric cancer characterized by elevated levels of HER2 proteins.

HER2 positive breast cancers are typically more aggressive. The targeted therapy for HER2 positive breast cancer functions by specifically targeting the proteins responsible for the growth, development, and dissemination of cancer. It is advised to use effective birth control during treatment and for at least 7 months following the last dose.

Canmab 440mg Injection is not recommended for individuals under 18 years of age, those with severe respiratory issues, or patients requiring oxygen therapy. It is crucial to inform your physician if you have any heart conditions, experience breathlessness, or have previously undergone any other cancer treatments. Ensure that you disclose all medications, including supplements and herbal products, you are currently taking before commencing treatment with this medication.